LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

240.84 1.69

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

231.16

Max

241.4

Belangrijke statistieken
By Trading Economics
Inkomsten	28M -33M
Verkoop	32M 245M
Winstmarge	-13.56
Werknemers	1,189
EBITDA	68M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+23.59% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.3B 15B
Vorige openingsprijs	239.15
Vorige sluitingsprijs	240.84

Nieuwssentiment

By Acuity

54%

46%

279 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 19:32 UTC

Acquisities, Fusies, Overnames

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mrt 2026, 22:26 UTC

Belangrijke Nieuwsgebeurtenissen

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mrt 2026, 22:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

6 mrt 2026, 21:37 UTC

Winsten

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mrt 2026, 21:25 UTC

Belangrijke Nieuwsgebeurtenissen

How The Iran War Impacts Ukraine. -- Barrons.com

6 mrt 2026, 21:17 UTC

Winsten

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mrt 2026, 20:50 UTC

Winsten

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mrt 2026, 20:46 UTC

Winsten

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mrt 2026, 20:31 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mrt 2026, 20:18 UTC

Marktinformatie

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mrt 2026, 20:12 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mrt 2026, 19:10 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mrt 2026, 18:54 UTC

Marktinformatie

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mrt 2026, 18:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mrt 2026, 18:08 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 17:49 UTC

Marktinformatie

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mrt 2026, 17:46 UTC

Belangrijke Nieuwsgebeurtenissen

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mrt 2026, 17:40 UTC

Marktinformatie

Winsten

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mrt 2026, 17:40 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 17:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mrt 2026, 17:28 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Acquisities, Fusies, Overnames

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

23.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 293.33 USD 23.59%

Hoogste 342 USD

Laagste 255 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

279 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.